Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial

Journal of the American College of Cardiology

Volumn 69, Issue 5, 2017, Pages 526-537

  Hare, Joshua M ^a   DiFede, Darcy L ^a   Rieger, Angela C ^a   Florea, Victoria ^a   Landin, Ana M ^a   El Khorazaty, Jill ^b   Khan, Aisha ^a   Mushtaq, Muzammil ^a   Lowery, Maureen H ^a   Byrnes, John J ^a   Hendel, Robert C ^a   Cohen, Mauricio G ^a   Alfonso, Carlos E ^a   Valasaki, Krystalenia ^a   Pujol, Marietsy V ^a   Golpanian, Samuel ^a   Ghersin, Eduard ^a   Fishman, Joel E ^a   Pattany, Pradip ^a   Gomes, Samirah A ^a   Delgado, Cindy ^a   Miki, Roberto ^a   Abuzeid, Fouad ^a   Vidro Casiano, Mayra ^a   Premer, Courtney ^a   Medina, Audrey ^a   Porras, Valeria ^a   Hatzistergos, Konstantinos E ^a   Anderson, Erica ^b   Mendizabal, Adam ^b   Mitrani, Raul ^a   Heldman, Alan W ^a   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

endothelial function; heart failure; idiopathic dilated cardiomyopathy; immune biomarker; stem cell therapy

Indexed keywords

PANEL REACTIVE ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ALLOGENEIC MESENCHYMAL STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS MESENCHYMAL STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEATH; FEMALE; GRAFT RECIPIENT; HEART EJECTION FRACTION; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTERMETHOD COMPARISON; LEFT VENTRICULAR ASSIST DEVICE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; NONISCHEMIC DILATED CARDIOMYOPATHY; OPEN STUDY; PATIENT SAFETY; PERICARDIAL EFFUSION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; SUBDURAL HEMATOMA; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; UNITED STATES; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CARDIOMYOPATHY, DILATED; COMPARATIVE STUDY; PROCEDURES; SAFETY; TREATMENT OUTCOME;

CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; SAFETY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85011650223     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.11.009     Document Type: Article

References (34)

1. 1 Felker, G.M., Thompson, R.E., Hare, J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000), 1077–1084.
2. 2 Kirklin, J.K., Cantor, R., Mohacsi, P., et al. First Annual IMACS Report: a global International Society for Heart and Lung Transplantation Registry for Mechanical Circulatory Support. J Heart Lung Transplant 35 (2016), 407–412.
3. 3 Patel, A.N., Henry, T.D., Quyyumi, A.A., et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet 387 (2016), 2412–2421.
4. 4 Assmus, B., Honold, J., Schachinger, V., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355 (2006), 1222–1232.
5. 5 Hare, J.M., Traverse, J.H., Henry, T.D., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54 (2009), 2277–2286.
6. 6 Heldman, A.W., DiFede, D.L., Fishman, J.E., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311 (2014), 62–73.
7. 7 Perin, E.C., Willerson, J.T., Pepine, C.J., et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 307 (2012), 1717–1726.
8. 8 Golpanian, S., Wolf, A., Hatzistergos, K.E., Hare, J.M., Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol Rev 96 (2016), 1127–1168.
9. 9 Hare, J.M., Fishman, J.E., Gerstenblith, G., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308 (2012), 2369–2379.
10. 10 Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., Ringden, O., HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31 (2003), 890–896.
11. 11 Efthimiadis, I., Skendros, P., Sarantopoulos, A., Boura, P., CD4+/CD25+T-lymphocytes and Th1/Th2 regulation in dilated cardiomyopathy. Hippokratia 15 (2011), 335–342.
12. 12 Meng, X., Yang, J., Dong, M., et al. Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol 13 (2016), 167–179.
13. 13 Huang, X.P., Sun, Z., Miyagi, Y., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122 (2010), 2419–2429.
14. 14 Murphy, M.B., Moncivais, K., Caplan, A.I., Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Mol Med, 45, 2013, e54.
15. 15 Premer, C., Blum, A., Bellio, M.A., et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine 2 (2015), 467–475.
16. 16 Mushtaq, M., DiFede, D.L., Golpanian, S., et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res 7 (2014), 769–780.
17. 17 Schachinger, V., Assmus, B., Erbs, S., et al. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the Reinfusion of Enriched Progenitor Cells and Infarct Remodelling in Acute Myocardial Infarction (REPAIR-AMI) trial. Eur J Heart Fail 11 (2009), 973–979.
18. 18 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
19. 19 Kalogeropoulos, A.P., Fonarow, G.C., Georgiopoulou, V., et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 1 (2016), 510–518.
20. 20 Lund, L.H., Edwards, L.B., Dipchand, A.I., et al. The Registry of the International Society for Heart and Lung Transplantation: 33rd Adult Heart Transplantation Report — 2016;focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant 35 (2016), 1158–1169.
21. 21 Kelkar, A.A., Butler, J., Schelbert, E.B., et al. Mechanisms contributing to the progression of ischemic and nonischemic dilated cardiomyopathy: possible modulating effects of paracrine activities of stem cells. J Am Coll Cardiol 66 (2015), 2038–2047.
22. 22 Levine, B., Kalman, J., Mayer, L., Fillit, H.M., Packer, M., Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990), 236–241.
23. 23 Haudek, S.B., Taffet, G.E., Schneider, M.D., Mann, D.L., TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest 117 (2007), 2692–2701.
24. 24 Mann, D.L., McMurray, J.J., Packer, M., et al. Targeted anticytokine therapy in patients with chronic heart failure results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004), 1594–1602.
25. 25 Fan, L., Hu, C., Chen, J., Cen, P., Wang, J., Li, L., Interaction between mesenchymal stem cells and B-cells. Int J Mol Sci, 17, 2016, 650.
26. 26 Hatzistergos, K.E., Saur, D., Seidler, B., et al. Stimulatory effects of mesenchymal stem cells on cKit+ cardiac stem cells are mediated by SDF1/CXCR4 and SCF/cKit signaling pathways. Circ Res 119 (2016), 921–930.
27. 27 Nield, L.E., von Both, I., Popel, N., et al. Comparison of immune profiles in fetal hearts with idiopathic dilated cardiomyopathy, maternal autoimmune-associated dilated cardiomyopathy and the normal fetus. Pediatr Cardiol 37 (2016), 353–363.
28. 28 Frasca, D., Diaz, A., Romero, M., et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 28 (2010), 8077–8084.
29. 29 Johnson, S.A., Cambier, J.C., Ageing, autoimmunity and arthritis: senescence of the B cell compartment: implications for humoral immunity. Arthritis Res Ther 6 (2004), 131–139.
30. 30 Ascheim, D.D., Gelijns, A.C., Goldstein, D., et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 129 (2014), 2287–2296.
31. 31 Fischer-Rasokat, U., Assmus, B., Seeger, F.H., et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail 2 (2009), 417–423.
32. 32 Perin, E.C., Borow, K.M., Silva, G.V., et al. A phase ii dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res 117 (2015), 576–584.
33. 33 Seth, S., Bhargava, B., Narang, R., et al. The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial: a long-term follow-up study. J Am Coll Cardiol 55 (2010), 1643–1644.
34. 34 Vrtovec, B., Poglajen, G., Sever, M., et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail 17 (2011), 272–281.